MedPath

Is Bone Scintigraphy Necessary in cT1N0M0 GGO Non-Small Cell Lung Cancer? (ECTOP-1006)

Completed
Conditions
Bone Metastases
Registration Number
NCT03689439
Lead Sponsor
Fudan University
Brief Summary

This is a clinical trial from Eastern Cooperative Thoracic Oncology Project (ECTOP), numbered as ECTOP-1006. In this prospective one-arm observational study, bone scintigraphy will be performed in T1N0M0 NSCLC patients with GGO lesion and other low risk factors of bone metastasis. The occurrence rate of bone metastasis in these patients will be analyzed to evaluate the necessity of bone scintigraphy in cT1N0M0 NSCLC patients.

Detailed Description

Skeletal is a common metastatic site in patients with non-small cell lung cancer. The incidence of bone metastases is about 20-30% in NSCLC patients. According to the NCCN guidelines, early lung cancer patients should also undergo bone scan or PETCT before surgery to determine the presence of bone metastases. However, all of the above methods use radionuclide reagents as tracers, which pose health hazards to patients and their contacts, including medical personnel. A retrospective study conducted by our center showed that only 0.95% of patients with cT1N0M0 non-small cell lung cancer had preoperative bone metastases. In patients with early stage lung cancer whose lesions are pure ground glass nodules, the probability of developing bone metastases is zero. The low risk factors for bone metastases from this retrospective study included preoperative examination of patients with CEA \<5 ng/ul and no bone-related symptoms. In patients with primary NSCLC who underwent CEA \<5 ng/ul preoperatively, no bone metastases occurred; in patients with negative bone-related symptoms, the incidence of bone metastases was only 0.18%. In the case of such patients, if the bone scan is performed, not only the potential damage to the patient is increased, but also the waste of medical resources and the burden on the patient from the perspective of health economics.

Therefore, our center is expected to conduct this prospective one-arm observational clinical trial. According to the low-risk factors derived from retrospective studies, bone scintigraphy was performed in patients with GGO lesion and other low risk factors of bone metastasis, and the incidence of bone metastasis was obtained. The necessity of bone scintigraphy in cT1N0M0 NSCLC patients would be evaluated.

This trial is recognizes in our institute as "Eastern Cooperative Thoracic Oncology Project (ECTOP-1006)"

Recruitment & Eligibility

Status
COMPLETED
Sex
All
Target Recruitment
1000
Inclusion Criteria
  1. Patients who sign the informed consent form and are willing to complete the study according to the plan;
  2. Age 18-80 years old;
  3. ECOG score ≤ 2 points;
  4. CT shows that the main lesion is considered to be ground glass nodular lung cancer;
  5. Preoperative examination CEA <5ng/ul
  6. There are no bone related symptoms
  7. There is no obvious absolute surgical contraindication for preoperative examination.
Read More
Exclusion Criteria
  1. History of bone related diseases.
  2. History of other kinds of cancer
Read More

Study & Design

Study Type
OBSERVATIONAL
Study Design
Not specified
Primary Outcome Measures
NameTimeMethod
The Occurrence Rate of Bone metastasis in cT1N0M0 NSCLC patients1 month

The Number of cT1N0M0 NSCLC patients that had bone metastasis in this cohort

Secondary Outcome Measures
NameTimeMethod

Trial Locations

Locations (5)

Jiang Du People's Hospital

🇨🇳

Yangzhou, Jiang Su, China

Jilin Cancer Hospital

🇨🇳

Changchun, China

Henan Cancer Hospital

🇨🇳

Zhengzhou, He Nan, China

Anhui Chest Hospital

🇨🇳

Hefei, An Hui, China

Fudan University Cancer Center

🇨🇳

Shanghai, Shanghai, China

© Copyright 2025. All Rights Reserved by MedPath